New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide. …
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 Australian Biotech
Latest Video
New Stories
-
Can GLP-1s be more transformative than AI - one person believes they already are
July 14, 2026 - - Latest News -
The age-old argument for supermarket pharmacies misses the point, and the risks
July 14, 2026 - - Latest News -
Pharmacy Guild rejects Grattan Institute report, describing community pharmacies as essential health providers
July 13, 2026 - - Latest News -
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 - - Australian Biotech -
OncoSil Medical establishes scalable Australian production after successful manufacturing validation
July 13, 2026 - - Australian Biotech -
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 - - Australian Biotech -
Patrys and Yale agree revenue share to advance deoxymab platform
July 13, 2026 - - Australian Biotech